Prof. Richard Greil MD
Head of the IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Assoc. Prof. Gabriel Rinnerthaler MD
IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer, Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Priv.-Doz. Simon P. Gampenrieder MD
IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Prof. Peter Schmid FRCP MD PhD
Centre Lead, Centre for Experimental Cancer Medicine, Director, Breast Cancer, St Bartholomew, Hospital London, London, United Kingdom
Prof. Dipl.-Ing. Dr. Zlatko Trajanoski
Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Austria
Marleen Kok MD PhD
Medical Oncologist and Research Group Leader, Cancer Immunotherapy of the Dutch Cancer Society, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Prof. Eric Vivier DVM PhD
Professor, Aix Marseille Univ, CNRS, INSERM, Centre d’Immunologie de Marseille, Marseille Immunopole, Scientific Director- Innate Pharma Research Labs and President- Paris-Saclay Cancer Cluster
Marseille, France
Prof. Dr. Niels Schaft PhD
Research Group Leader of the RNA-based Immunotherapy group, Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Prof. Dr. Udo Gaipl
Head of Translational Radiobiology, Universitätsklinikum Erlangen, Department of Radiation Oncology, Erlangen, Germany
Dr. Iosifina Foskolou
Group Leader at Sanquin Research, Amsterdam, The Netherlands
Prof. Laurence Zitvogel MD PhD
Gustave Roussy Comprehensive Cancer Institute, Villejuif, France
Université Paris Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France, INSERM U1015, Villejuif, France
Dr. Roberto Salgado
Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium; Division of Research, Peter Mac Callum Cancer Center, Melbourne, Australia
Prof. Dr. Barbara Seliger
Director of the Institute for Medical Immunology, Martin Luther University, Medical Faculty, Halle, Germany
Karen Willard-Gallo MD PhD
Head, Molecular Immunology Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
12:30 – 13:30 Welcome & Business Lunch
13:30 – 13:35 Introduction
Richard Greil, Salzburg
13:35 – 15:45 Combination strategies
Chair: Gabriel Rinnerthaler, Simon Gampenrieder
Conception of clinical trials investigating immunotherapy
tba
Immune checkpoint inhibitors beyond PD-1/PD-L1
tba
Immune checkpoint inhibitor + ADC
Peter Schmid (London)
Dissecting tumor microenvironment, one cell at a time
Zlatko Trajanoski (Innsbruck)
Panel-Discussion
All speakers
Moderator: Richard Greil (Salzburg)
15:45 – 16:15 Coffee Break
16:15 – 18:30 Novel and old therapeutic approaches
Chair: tba
Priming the immune system for IO response
Marleen Kok (Amsterdam)
NK cell targeted therapy
Eric Vivier (Marseille)
CAR T-Cells
Niels Schaft (Erlangen)
Abscopal effect – true or overrated?
Udo Gaipl (Erlangen)
Panel-Discussion
All speakers
Moderator: Richard Greil (Salzburg)
08:30 – 10:15 Metabolism & Immunogenicity
Chair: tba
2-hydroxyglutarate and other metabolites*
Iosifina Foskolou (Cambridge)
Targeting TGFβ*
tba
Targeting the microbioma to improve immunotherapy efficacy*
Laurence Zitvogel (Paris)
*Discussion after lecture
10:15 – 10:45 Coffee break
10:45 – 13:00 Biomarker
Chair: tba
TILs vs PDL1: what is the best pragmatic approach in daily practices?
Roberto Salgado (Antwerp)
MHC class I loss
Barbara Seliger (Halle)
Tertiary lymphoid structures
Karen Willard Gallo (Brussels)
Immune Cell Composition
tba
Panel discussion
All speakers
Moderator: Richard Greil (Salzburg)
Closing Remarks
Richard Greil (Salzburg)
13:00 – 14:00 Business Lunch & Farewell
The registration form is now available, we look forward to your submission. We would like to point out that this conference is not open to the public. After your registration your entries will be checked by us, followed by information about your requested participation.
5th SALZBURG BREAST CANCER TALK – Mastering translational Immuno-Oncology is applied for 11 DFP points at the Diploma Continuing Education Programme of the Austrian Medical Association (ÖÄK).
Hotel Gersbergalm
Gersberg 37
5020 Salzburg
The hotel can be reached by car (sufficient parking available), by bus (line 151) or by cab (still city area).
Prof. Dr. Richard Greil
Dr. Simon P. Gampenrieder
Dr. Gabriel Rinnerthaler
Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)
in Kooperation mit
Cancer Cluster Salzburg | www.cancercluster-salzburg.at
Photos: Franz Neumayr
POSTPONED DUE TO SARS-CoV-2 Due to the current situation concerning the coronavirus epidemic and the resulting travel restrictions of even already planned speakers, we have decided to reschedule our event „Salzburg Breast Cancer Talk“ to October 2022....
Die Veranstaltung 3rd SALZBURG BREAST CANCER TALK, MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY vom 01. bis 02.03.2019, im PITTER Event Center Salzburg war mit über 100 Teilnehmern wieder ein voller Erfolg. Die Vortragenden, alle auf ihrem Fachgebiet international renommierte Wissenschaftler, verstanden es eindrucksvoll, dem fachkundigen Publikum Einblicke in ihre Forschung am Puls der Zeit zu gewähren. Die Disskusionsrunden […]...
01.- 02.03.2019 Salzburg — MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY...
